nodes	percent_of_prediction	percent_of_DWPC	metapath
Clenbuterol—TNF—psoriasis	0.513	1	CbGaD
Clenbuterol—CYP1A1—Clobetasol propionate—psoriasis	0.143	0.37	CbGbCtD
Clenbuterol—CYP1A1—Methoxsalen—psoriasis	0.0753	0.194	CbGbCtD
Clenbuterol—CYP1A2—Clobetasol propionate—psoriasis	0.0641	0.165	CbGbCtD
Clenbuterol—CYP1A1—Cholecalciferol—psoriasis	0.0499	0.129	CbGbCtD
Clenbuterol—CYP1A2—Methoxsalen—psoriasis	0.0336	0.0867	CbGbCtD
Clenbuterol—CYP1A1—Dexamethasone—psoriasis	0.0216	0.0557	CbGbCtD
Clenbuterol—TNF—TNF receptor signaling pathway —NFKB1—psoriasis	0.000177	0.00178	CbGpPWpGaD
Clenbuterol—TNF—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000177	0.00178	CbGpPWpGaD
Clenbuterol—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000176	0.00178	CbGpPWpGaD
Clenbuterol—NGF—Signaling by NGF—NFKBIA—psoriasis	0.000176	0.00178	CbGpPWpGaD
Clenbuterol—TNF—Adipogenesis—SOCS1—psoriasis	0.000175	0.00177	CbGpPWpGaD
Clenbuterol—TNF—IL27-mediated signaling events—IL6—psoriasis	0.000175	0.00176	CbGpPWpGaD
Clenbuterol—NGF—BDNF signaling pathway—STAT3—psoriasis	0.000175	0.00176	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000173	0.00174	CbGpPWpGaD
Clenbuterol—NGF—MAPK Signaling Pathway—NFKB1—psoriasis	0.000172	0.00173	CbGpPWpGaD
Clenbuterol—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	0.000172	0.00173	CbGpPWpGaD
Clenbuterol—TNF—Transcriptional regulation of white adipocyte differentiation—PPARG—psoriasis	0.000171	0.00173	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—NFKBIA—psoriasis	0.000171	0.00172	CbGpPWpGaD
Clenbuterol—TNF—Ceramide signaling pathway—NFKB1—psoriasis	0.000171	0.00172	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—CCL20—psoriasis	0.00017	0.00172	CbGpPWpGaD
Clenbuterol—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	0.00017	0.00171	CbGpPWpGaD
Clenbuterol—TNF—Cytokines and Inflammatory Response—IL6—psoriasis	0.00017	0.00171	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—HCAR2—psoriasis	0.000168	0.0017	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—TAGAP—psoriasis	0.000167	0.00168	CbGpPWpGaD
Clenbuterol—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000166	0.00168	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—SOCS1—psoriasis	0.000166	0.00167	CbGpPWpGaD
Clenbuterol—TNF—Selenium Micronutrient Network—ICAM1—psoriasis	0.000166	0.00167	CbGpPWpGaD
Clenbuterol—NGF—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000166	0.00167	CbGpPWpGaD
Clenbuterol—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000165	0.00167	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—IL4—psoriasis	0.000165	0.00167	CbGpPWpGaD
Clenbuterol—TNF—Angiopoietin receptor Tie2-mediated signaling—NFKB1—psoriasis	0.000165	0.00167	CbGpPWpGaD
Clenbuterol—TNF—Vitamin B12 Metabolism—NFKB1—psoriasis	0.000163	0.00164	CbGpPWpGaD
Clenbuterol—TNF—TGF-beta Receptor Signaling—JUN—psoriasis	0.000161	0.00163	CbGpPWpGaD
Clenbuterol—TNF—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.00016	0.00162	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—IFNG—psoriasis	0.000159	0.0016	CbGpPWpGaD
Clenbuterol—TNF—Downstream signaling in naïve CD8+ T cells—IFNG—psoriasis	0.000159	0.0016	CbGpPWpGaD
Clenbuterol—TNF—TNF alpha Signaling Pathway—NFKBIA—psoriasis	0.000159	0.0016	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—NFKB1—psoriasis	0.000158	0.00159	CbGpPWpGaD
Clenbuterol—TNF—TGF-beta Receptor Signaling—NFKB1—psoriasis	0.000155	0.00157	CbGpPWpGaD
Clenbuterol—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000155	0.00156	CbGpPWpGaD
Clenbuterol—TNF—Cardiac Hypertrophic Response—NFKB1—psoriasis	0.000153	0.00154	CbGpPWpGaD
Clenbuterol—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000153	0.00154	CbGpPWpGaD
Clenbuterol—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000153	0.00154	CbGpPWpGaD
Clenbuterol—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.00015	0.00152	CbGpPWpGaD
Clenbuterol—TNF—amb2 Integrin signaling—IL6—psoriasis	0.000148	0.00149	CbGpPWpGaD
Clenbuterol—TNF—Toll-like Receptor Signaling Pathway—NFKBIA—psoriasis	0.000146	0.00148	CbGpPWpGaD
Clenbuterol—NGF—Signaling by NGF—TYK2—psoriasis	0.000144	0.00145	CbGpPWpGaD
Clenbuterol—NGF—SIDS Susceptibility Pathways—TNF—psoriasis	0.000142	0.00143	CbGpPWpGaD
Clenbuterol—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—psoriasis	0.000141	0.00142	CbGpPWpGaD
Clenbuterol—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	0.00014	0.00141	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—LEP—psoriasis	0.00014	0.00141	CbGpPWpGaD
Clenbuterol—TNF—TGF-beta Receptor Signaling—STAT3—psoriasis	0.00014	0.00141	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—IFNG—psoriasis	0.000138	0.00139	CbGpPWpGaD
Clenbuterol—TNF—Downstream signaling in naïve CD8+ T cells—JUN—psoriasis	0.000137	0.00139	CbGpPWpGaD
Clenbuterol—CYP1A1—Oxidative Stress—NFKB1—psoriasis	0.000136	0.00138	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—IL10—psoriasis	0.000136	0.00137	CbGpPWpGaD
Clenbuterol—NGF—MAPK Signaling Pathway—TNF—psoriasis	0.000134	0.00135	CbGpPWpGaD
Clenbuterol—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000134	0.00135	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000133	0.00134	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—NFKB1—psoriasis	0.000132	0.00133	CbGpPWpGaD
Clenbuterol—TNF—IL23-mediated signaling events—IL6—psoriasis	0.000132	0.00133	CbGpPWpGaD
Clenbuterol—NGF—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	0.000131	0.00132	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—ICAM1—psoriasis	0.000131	0.00132	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—NOS2—psoriasis	0.00013	0.00131	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00013	0.00131	CbGpPWpGaD
Clenbuterol—TNF—Adipogenesis—LEP—psoriasis	0.000129	0.0013	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—CXCL8—psoriasis	0.000128	0.00129	CbGpPWpGaD
Clenbuterol—TNF—Selenium Micronutrient Network—IFNG—psoriasis	0.000126	0.00127	CbGpPWpGaD
Clenbuterol—TNF—Signaling events mediated by HDAC Class I—NFKB1—psoriasis	0.000126	0.00127	CbGpPWpGaD
Clenbuterol—TNF—TWEAK Signaling Pathway—IL6—psoriasis	0.000119	0.0012	CbGpPWpGaD
Clenbuterol—NGF—MAPK Signaling Pathway—TP53—psoriasis	0.000118	0.00119	CbGpPWpGaD
Clenbuterol—TNF—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	0.000117	0.00118	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000116	0.00117	CbGpPWpGaD
Clenbuterol—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000115	0.00116	CbGpPWpGaD
Clenbuterol—NGF—SIDS Susceptibility Pathways—IL6—psoriasis	0.000115	0.00116	CbGpPWpGaD
Clenbuterol—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000114	0.00115	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—NFKBIA—psoriasis	0.000114	0.00115	CbGpPWpGaD
Clenbuterol—TNF—Signaling events mediated by HDAC Class I—STAT3—psoriasis	0.000113	0.00114	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—JUN—psoriasis	0.000113	0.00114	CbGpPWpGaD
Clenbuterol—TNF—Adipogenesis—PPARG—psoriasis	0.000113	0.00114	CbGpPWpGaD
Clenbuterol—NGF—Signaling by NGF—NFKB1—psoriasis	0.000112	0.00113	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—HCAR2—psoriasis	0.00011	0.00111	CbGpPWpGaD
Clenbuterol—TNF—MicroRNAs in cardiomyocyte hypertrophy—NFKB1—psoriasis	0.000109	0.0011	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—NFKB1—psoriasis	0.000109	0.0011	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—HCAR2—psoriasis	0.000108	0.00109	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000105	0.00106	CbGpPWpGaD
Clenbuterol—TNF—TNF alpha Signaling Pathway—JUN—psoriasis	0.000105	0.00106	CbGpPWpGaD
Clenbuterol—TNF—Selenium Micronutrient Network—NFKB1—psoriasis	0.000105	0.00106	CbGpPWpGaD
Clenbuterol—TNF—Toll-like Receptor Signaling Pathway—CXCL8—psoriasis	0.000104	0.00105	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—VEGFA—psoriasis	0.000104	0.00105	CbGpPWpGaD
Clenbuterol—TNF—Vitamin B12 Metabolism—IL6—psoriasis	0.000102	0.00103	CbGpPWpGaD
Clenbuterol—TNF—TNF alpha Signaling Pathway—NFKB1—psoriasis	0.000101	0.00102	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—CCL20—psoriasis	0.000101	0.00102	CbGpPWpGaD
Clenbuterol—NGF—Signaling by NGF—STAT3—psoriasis	0.000101	0.00102	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000101	0.00102	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—HCAR2—psoriasis	0.0001	0.00101	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CCL20—psoriasis	9.99e-05	0.00101	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—IFNG—psoriasis	9.99e-05	0.00101	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—HCAR2—psoriasis	9.95e-05	0.001	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—CCL20—psoriasis	9.9e-05	0.000998	CbGpPWpGaD
Clenbuterol—TNF—MicroRNAs in cardiomyocyte hypertrophy—STAT3—psoriasis	9.8e-05	0.000988	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—HCAR2—psoriasis	9.78e-05	0.000986	CbGpPWpGaD
Clenbuterol—TNF—Toll-like Receptor Signaling Pathway—JUN—psoriasis	9.7e-05	0.000978	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	9.69e-05	0.000977	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—CCL20—psoriasis	9.63e-05	0.000971	CbGpPWpGaD
Clenbuterol—TNF—Toll-like Receptor Signaling Pathway—NFKB1—psoriasis	9.34e-05	0.000941	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—CARM1—psoriasis	9.3e-05	0.000938	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—CXCL8—psoriasis	9.28e-05	0.000936	CbGpPWpGaD
Clenbuterol—NGF—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	9.17e-05	0.000925	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—TP53—psoriasis	9.07e-05	0.000915	CbGpPWpGaD
Clenbuterol—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	8.94e-05	0.000901	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	8.86e-05	0.000893	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	8.79e-05	0.000887	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—CCL20—psoriasis	8.75e-05	0.000882	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—TAGAP—psoriasis	8.63e-05	0.00087	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—IL6—psoriasis	8.3e-05	0.000837	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—CXCL8—psoriasis	8.14e-05	0.000821	CbGpPWpGaD
Clenbuterol—TNF—Alzheimers Disease—TP53—psoriasis	7.85e-05	0.000792	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—JUN—psoriasis	7.57e-05	0.000763	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	7.54e-05	0.00076	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	7.54e-05	0.00076	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—TP53—psoriasis	7.48e-05	0.000754	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—CXCL8—psoriasis	7.43e-05	0.000749	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	7.43e-05	0.000749	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—NFKB1—psoriasis	7.29e-05	0.000735	CbGpPWpGaD
Clenbuterol—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	7.07e-05	0.000712	CbGpPWpGaD
Clenbuterol—NGF—Signaling by NGF—IL6—psoriasis	7.05e-05	0.000711	CbGpPWpGaD
Clenbuterol—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	6.92e-05	0.000697	CbGpPWpGaD
Clenbuterol—TNF—Adipogenesis—STAT3—psoriasis	6.91e-05	0.000697	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—JUN—psoriasis	6.9e-05	0.000696	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—NFKB1—psoriasis	6.65e-05	0.00067	CbGpPWpGaD
Clenbuterol—TNF—Selenium Micronutrient Network—IL6—psoriasis	6.59e-05	0.000665	CbGpPWpGaD
Clenbuterol—TNF—MAPK Signaling Pathway—JUN—psoriasis	6.51e-05	0.000656	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	6.42e-05	0.000647	CbGpPWpGaD
Clenbuterol—TNF—TNF alpha Signaling Pathway—IL6—psoriasis	6.36e-05	0.000642	CbGpPWpGaD
Clenbuterol—TNF—MAPK Signaling Pathway—NFKB1—psoriasis	6.26e-05	0.000632	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	6.18e-05	0.000623	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	6.04e-05	0.00061	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—VEGFA—psoriasis	6.03e-05	0.000608	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—HCAR2—psoriasis	5.9e-05	0.000595	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	5.87e-05	0.000592	CbGpPWpGaD
Clenbuterol—TNF—Toll-like Receptor Signaling Pathway—IL6—psoriasis	5.86e-05	0.000591	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—HCAR2—psoriasis	5.78e-05	0.000582	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—CCL20—psoriasis	5.72e-05	0.000577	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—TP53—psoriasis	5.7e-05	0.000575	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	5.65e-05	0.00057	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	5.61e-05	0.000565	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—CCL20—psoriasis	5.59e-05	0.000564	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—SOCS1—psoriasis	5.5e-05	0.000555	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—IL6—psoriasis	5.22e-05	0.000526	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—CCL20—psoriasis	5.19e-05	0.000524	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CCL20—psoriasis	5.17e-05	0.000521	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	5.13e-05	0.000517	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—TAGAP—psoriasis	5.12e-05	0.000516	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—CCL20—psoriasis	5.08e-05	0.000512	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—TAGAP—psoriasis	5.01e-05	0.000505	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—NDUFA5—psoriasis	4.89e-05	0.000493	CbGpPWpGaD
Clenbuterol—TNF—Adipogenesis—IL6—psoriasis	4.83e-05	0.000487	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.81e-05	0.000485	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.81e-05	0.000485	CbGpPWpGaD
Clenbuterol—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	4.76e-05	0.00048	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—CXCL8—psoriasis	4.6e-05	0.000464	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—TP53—psoriasis	4.58e-05	0.000462	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	4.57e-05	0.000461	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.56e-05	0.00046	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—LEP—psoriasis	4.44e-05	0.000448	CbGpPWpGaD
Clenbuterol—TNF—MAPK Signaling Pathway—TP53—psoriasis	4.3e-05	0.000433	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—IL6—psoriasis	4.17e-05	0.000421	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—CYP2S1—psoriasis	4.16e-05	0.000419	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—APOE—psoriasis	4.06e-05	0.000409	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—LEP—psoriasis	4.06e-05	0.000409	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.88e-05	0.000391	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—PPARG—psoriasis	3.87e-05	0.00039	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—NFKBIA—psoriasis	3.78e-05	0.000381	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.59e-05	0.000362	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.51e-05	0.000354	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—TYK2—psoriasis	3.39e-05	0.000342	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—NDUFA5—psoriasis	3.12e-05	0.000314	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—TYK2—psoriasis	3.1e-05	0.000312	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CCL20—psoriasis	3.07e-05	0.000309	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CCL20—psoriasis	3e-05	0.000303	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.91e-05	0.000293	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—SOCS1—psoriasis	2.85e-05	0.000287	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—CXCL8—psoriasis	2.73e-05	0.000275	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—TYK2—psoriasis	2.71e-05	0.000274	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CXCL8—psoriasis	2.7e-05	0.000272	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—CXCL8—psoriasis	2.67e-05	0.000269	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—CYP2S1—psoriasis	2.65e-05	0.000267	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—NFKB1—psoriasis	2.64e-05	0.000266	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—CXCL8—psoriasis	2.6e-05	0.000262	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—JUN—psoriasis	2.51e-05	0.000253	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—NFKB1—psoriasis	2.41e-05	0.000243	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—VEGFA—psoriasis	2.4e-05	0.000242	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—STAT3—psoriasis	2.37e-05	0.000239	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—CXCL8—psoriasis	2.36e-05	0.000238	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—VEGFA—psoriasis	2.19e-05	0.000221	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.18e-05	0.00022	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—STAT3—psoriasis	2.17e-05	0.000219	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—LEP—psoriasis	2.1e-05	0.000212	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—APOE—psoriasis	2.1e-05	0.000212	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—CARM1—psoriasis	2.03e-05	0.000205	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—NFKBIA—psoriasis	1.96e-05	0.000197	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.9e-05	0.000191	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—SOCS1—psoriasis	1.69e-05	0.00017	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—IL6—psoriasis	1.66e-05	0.000167	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—TP53—psoriasis	1.66e-05	0.000167	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—SOCS1—psoriasis	1.65e-05	0.000167	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—TYK2—psoriasis	1.61e-05	0.000162	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—TYK2—psoriasis	1.6e-05	0.000162	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—TYK2—psoriasis	1.58e-05	0.000159	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—CXCL8—psoriasis	1.54e-05	0.000156	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—IL6—psoriasis	1.52e-05	0.000153	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—CXCL8—psoriasis	1.51e-05	0.000152	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—CXCL8—psoriasis	1.4e-05	0.000141	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CXCL8—psoriasis	1.4e-05	0.000141	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.39e-05	0.00014	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—CXCL8—psoriasis	1.37e-05	0.000138	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—IL6—psoriasis	1.33e-05	0.000134	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—JUN—psoriasis	1.3e-05	0.000131	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—CARM1—psoriasis	1.29e-05	0.000131	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—NFKB1—psoriasis	1.25e-05	0.000126	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—CAT—psoriasis	1.25e-05	0.000126	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—APOE—psoriasis	1.25e-05	0.000126	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—LEP—psoriasis	1.25e-05	0.000126	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—LEP—psoriasis	1.22e-05	0.000123	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—APOE—psoriasis	1.22e-05	0.000123	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.21e-05	0.000122	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—NFKBIA—psoriasis	1.16e-05	0.000117	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—NFKBIA—psoriasis	1.14e-05	0.000115	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—VEGFA—psoriasis	1.13e-05	0.000114	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—STAT3—psoriasis	1.12e-05	0.000113	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—APOE—psoriasis	9.7e-06	9.78e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—TYK2—psoriasis	9.51e-06	9.59e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—TYK2—psoriasis	9.31e-06	9.38e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—TP53—psoriasis	8.56e-06	8.64e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—PPARG—psoriasis	8.45e-06	8.52e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CXCL8—psoriasis	8.28e-06	8.35e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CXCL8—psoriasis	8.1e-06	8.17e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—CAT—psoriasis	7.96e-06	8.03e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—IL6—psoriasis	7.88e-06	7.94e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—IL6—psoriasis	7.84e-06	7.9e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—IL6—psoriasis	7.7e-06	7.77e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—JUN—psoriasis	7.7e-06	7.76e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—JUN—psoriasis	7.53e-06	7.6e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—NFKB1—psoriasis	7.41e-06	7.47e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—NFKB1—psoriasis	7.25e-06	7.31e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—VEGFA—psoriasis	6.73e-06	6.78e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—STAT3—psoriasis	6.66e-06	6.72e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—VEGFA—psoriasis	6.58e-06	6.64e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—STAT3—psoriasis	6.52e-06	6.57e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—APOE—psoriasis	6.19e-06	6.24e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—PPARG—psoriasis	5.39e-06	5.43e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—TP53—psoriasis	5.08e-06	5.13e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—TP53—psoriasis	4.97e-06	5.01e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—IL6—psoriasis	4.65e-06	4.69e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—IL6—psoriasis	4.55e-06	4.59e-05	CbGpPWpGaD
